US Stocks Movement | Argenx (ARGX.US) rises over 10% pre-market as Phase III study of autoimmune myositis drug Vyvgart meets primary endpoint

智通财经2026/08/17 11:01

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

According to Golden Ten Data APP, before the U.S. stock market opened on Monday, the stock price of European biotechnology company Argenx (ARGX.US) surged by 10.38%. According to reports, the company announced on Monday that its autoimmune myositis drug Vyvgart reached the primary endpoint in a Phase III study.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Anthropic's IPO roadshow received strong investor demand within less than a day, prompting underwriters to consider raising the offering price to above $78 per share. The company’s valuation is expected to surpass 1.5 trillions USD, with total fundraising likely to exceed 100 billions USD. According to three Anthropic shareholders, the company's main goal is to raise as much capital as possible to support its extensive computing power expenditure plans.

华尔街见闻•2026/11/11 04:12